Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection.

Abstract

We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient's hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.

• Authors: Yasuyo Kashiwagi, Hisashi Kawashima, Junya Nakajima, Yu Ishida, Shigeo Nishimata, Tasuku Miyajima, Kouji Takekuma, Akinori Hoshika, Naoki Inoue
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 17 Issue 4 Pg. 538-40 (Aug 2011) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 21229284 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiviral Agents
• DNA, Viral
• Valganciclovir
• Ganciclovir

Topics

• Antiviral Agents (administration & dosage)
• Brain (diagnostic imaging)
• Cytomegalovirus (genetics, isolation & purification)
• Cytomegalovirus Infections (congenital, diagnostic imaging, drug therapy, virology)
• DNA, Viral (blood, urine)
• Evoked Potentials, Auditory, Brain Stem
• Ganciclovir (administration & dosage, analogs & derivatives)
• Hearing Loss (virology)
• Humans
• Infant, Newborn
• Infant, Newborn, Diseases (diagnostic imaging, drug therapy, virology)
• Magnetic Resonance Imaging
• Male
• Radiography
• Valganciclovir
• Viral Load